CCR News and Events

T-cell stimulation could be used to target cancers with common TP53 gene mutations

Researchers in the Center for Cancer Research have found that circulating lymphocytes can be stimulated in the laboratory to generate cells that can recognize TP53 gene mutations. Mutations to the TP53 gene are found in about 40 percent of all cancers, making this process a potentially significant step forward in fighting many types of cancer. Read more...

HIV infecting healthy cell

Unlocking the key to HIV persistence

Dec 2, 2019

Even though antiretroviral therapies have allowed many people to live long lives, ridding the body of HIV completely has been an elusive goal ever since the discovery in the 1980s that HIV causes AIDS. New research from the Center for Cancer Research shows that proviral DNA sequences and their integration at specific sites could provide clues for researchers developing drugs to eradicate AIDS.  Read more...

T cells

Clinical trial evaluates T-cell therapy for advanced mesothelin-expressing cancers

Nov 26, 2019

Some cancer cells express a higher-than-normal amount of mesothelin, which makes them more likely to multiply and spread to other parts of the body. Raffit Hassan, M.D., of the Thoracic and GI Malignancies Branch, is leading a trial that tests T-cell immunotherapy for patients with cancer of the lung and its lining, ovarian cancer and bile duct cancer that express high levels of mesothelin. Read more...

Mitochondrial shape in pancreatic cancer

Computational analysis leads to potential new drug combination for pancreatic cancer

Nov 20, 2019

A computer analysis has been able to predict that low levels of asparagine, an amino acid required for protein synthesis, combined with the shutdown of a stress response pathway can lead to reductions in the fitness of a tumor. These combined findings could potentially lead to new combination therapies to treat aggressive tumors, such as those found in pancreatic cancers. Read more...

Prostate imaging

Clinical trial will test radiotracer imaging for high-risk localized prostate cancer

Nov 19, 2019

Many men with prostate cancer are diagnosed at an early stage of the disease when the cancer is confined to the prostate. However, about 20 percent are diagnosed with high-risk disease, which tends to spread, or metastasize, to other parts of the body. William Dahut, M.D., Senior Investigator in the Genitourinary Malignancies Branch, is leading a study using positron emission tomography/computed tomography (PET/CT) with radioactive material to try and identify places in the body where prostate cancer has spread. Read more...

Fusing a ring system onto an existing chromophore

New video: Discovering new far-red fluorescent probes

Nov 18, 2019

Fluorescent probes are workhorse molecules used by biologists to illuminate the inner workings of cancer cells. By lighting up cell components of interest, researchers can then observe cells in action through high-powered microscopes. This new video explains a novel class of far-red fluorescent probes synthesized by Martin Schnermann, Ph.D., Senior Investigator in CCR’s Chemical Biology Laboratory, and his team. Read more...

hairy cell leukemia

Clinical trial tests combination therapy for relapsed hairy cell leukemia

Nov 15, 2019

Hairy cell leukemia (HCL) is a rare and slow-growing leukemia in which bone marrow overproduces abnormal B lymphocytes, a type of white blood cell. Under a microscope, these malignant cells appear to be covered with tiny hair-like projections. In this study, patients will receive an immunotoxin called moxetumomab pasudotox to study its effect on relapsed HCL. Read more...

pancreatic cancer cells

Pancreatic Cancer Research

Nov 4, 2019

November is Pancreatic Cancer Awareness Month. We have many researchers, both in the basic and clinical disciplines, who are working on pancreatic cancer.  Learn more...

Lung cancer cells

Lung Cancer Research

Nov 4, 2019

November is Lung Cancer Awareness Month. Our research portfolio includes investigators making important discoveries in lung cancer research.  Read more...

Elaine Jaffe

Elaine Jaffe named an NIH Distinguished Investigator

Oct 29, 2019

Elaine Jaffe, M.D., Senior Investigator in the Laboratory of Pathology, has been selected as an NIH Distinguished Investigator, a prestigious title reserved for tenured intramural senior investigators who are at the highest level in their fields. Dr. Jaffe has conducted pioneering studies related to the classification of malignant lymphomas and has led an international effort for consensus among clinicians and pathologists. Read more...

Pancreatic cancer cells

Clinical trial will test new treatment to improve survival rates for patients with operable gastrointestinal tumors

Oct 28, 2019

A clinical phase II trial at the NIH Clinical Center will test the effectiveness of a monoclonal antibody used immediately before and after surgery for patients with primary pancreatic and bile duct cancer and those who have liver metastasis from colorectal cancer. The trial is investigating whether this treatment can prevent the disease from coming back after surgery. Read more...

Pages